Ameriprise Financial Inc. Has $6.10 Million Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Ameriprise Financial Inc. decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 20.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 97,885 shares of the company’s stock after selling 24,717 shares during the quarter. Ameriprise Financial Inc. owned 0.29% of TransMedics Group worth $6,103,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in TMDX. Park Avenue Securities LLC lifted its position in shares of TransMedics Group by 3.8% during the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock worth $548,000 after buying an additional 322 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $239,000. Cornerstone Wealth Management LLC bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $231,000. Sachetta LLC bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $40,000. Finally, Perigon Wealth Management LLC lifted its holdings in TransMedics Group by 212.4% during the 4th quarter. Perigon Wealth Management LLC now owns 14,277 shares of the company’s stock valued at $828,000 after purchasing an additional 9,707 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Up 0.7%

Shares of NASDAQ TMDX opened at $124.25 on Friday. The company has a market cap of $4.20 billion, a PE ratio of 132.18 and a beta of 1.91. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a 50-day moving average of $89.57 and a two-hundred day moving average of $77.29.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s quarterly revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.35 earnings per share. As a group, equities analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMDX. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Piper Sandler reiterated an “overweight” rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Finally, Oppenheimer lifted their price objective on TransMedics Group from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.70.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director David Weill sold 732 shares of the business’s stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director now directly owns 12,134 shares of the company’s stock, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.